2,4-difluoro-N-(2-methoxy-5-(4-(4-((1R,4R)-3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbonyl)phenyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide | 1313993-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,4-difluoro-N-(2-methoxy-5-(4-(4-((1R,4R)-3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbonyl)phenyl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide
• 英文别名: 2,4-difluoro-N-[2-methoxy-5-[4-[4-[(1R,4R)-3-oxo-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbonyl]phenyl]quinolin-6-yl]pyridin-3-yl]benzenesulfonamide
• CAS: 1313993-07-5
• 化学式: C₃₃H₂₄F₂N₄O₆S
• 分子量: 642.64
• InChiKey: MFHXRBJKVXEOAC-RNWIMVQKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  46
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN
  申请人：Petter Russell C.

  公开号：US20110269244A1

  公开（公告）日：2011-11-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

  本发明涉及酶抑制剂。更具体地说，本发明涉及配体导向的蛋白共价修饰；相同设计方法；相同的药物配方；以及使用方法。
• Ligand-Directed Covalent Modification of Protein
  申请人：Celgene CAR LLC

  公开号：US20170218353A1

  公开（公告）日：2017-08-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
• [EN] LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN<br/>[FR] MODIFICATION COVALENTE DE PROTÉINE, DIRIGÉE SUR UN LIGAND
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011082285A1

  公开（公告）日：2011-07-07

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.